We have observed
17 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after July 25, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
TREATMENT OF SOLID TUMOURS
PROTEASOME DEUBIQUINATING INHIBITOR SCREENING
TREATMENT OF PSORIASIS
METHOD FOR INHIBITION OF DEUBIQUITINATING ACTIVITY
SAFETY FLUID CONNECTOR FOR AN EXTRACORPOREAL FLUID LINE
LIQUID CARRIER FOR ORAL DELIVERY OF A PHARMACOLOGICALLY ACTIVE AGENT
MEDICAL MICROELECTRODE, METHOD FOR ITS MANUFACTURE, AND USE THEREOF
MEANS AND METHOD FOR TREATING SOLID TUMOURS
LIQUID OAT BASE
COMBINATION PROBE FOR LOCALIZING, RECORDING AND STIMULATING A TARGET TISSUE
METHOD FOR PREPARATION OF LIRAGLUTIDE USING BAL LINKER
METHOD FOR PREPARATION OF PEPTIDES WITH PSWANG LINKER
METHOD FOR PREPARATION OF LIRAGLUTIDE
SAFETY SPRING AGGREGATE
METHOD FOR THE PREPARATION OF H-ARG(MIS)-OH
METHOD OF IMPLANTATION OF A MEDICAL DEVICE INTO NEURAL TISSUE